USANA HEALTH SCIENCES INC financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data USANA HEALTH SCIENCES INC files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2022	FY2022	FY2023	FY2023	FY2025
Revenue	1,006	1,047	1,189	1,061	1,135	1,186	999	921	855	925
Cost of revenue	180	179	201	188	209	218	194	177	161	201
Gross profit	826	868	989	873	926	969	805	744	693	724
Research and development	8.84	8.95	10.2	10.3	10.6	11.1	11.6	11.4	11.6	10.7
Selling, general and administrative	234	265	275	268	261	279	262	257	263	337
Operating expenses	687	735	800	727	749	798	697	651	627	687
Operating income	139	133	188	146	176	170	108	93.1	66.3	37.4
Interest expense	0.44	0.05	0.04	0.07	0.51	0.06	0.19	0.26	0.28	0.84
Interest income	1.48	2.19	4.43	4.71	2.54	2.52	3.79	9.64	11.3	2.42
Other non-operating income	-0.07	2.14	3.16	4.31	1.46	0.45	1.01	9.38	10	4.1
Pre-tax income	139	135	192	150	178	171	109	102	76.4	41.5
Income tax	38.5	72.1	65.3	50	53.3	54.1	39.3	38.7	34.3	30.1
Net income	100	62.5	126	101	125	117	69.4	63.8	42	10.8
EBITDA	152	149	205	161	190	183	121	106	80.9	70
EPS, basic	4.14	2.57	5.24	4.44	5.89	5.78	3.60	3.31	2.20	0.58
EPS, diluted	3.99	2.53	5.12	4.41	5.86	5.73	3.59	3.30	2.19	0.58
Shares, basic (weighted)	24.2	24.3	24.1	22.6	21.2	20.1	19.3	19.3	19.1	18.5
Shares, diluted (weighted)	25	24.7	24.6	22.8	21.3	20.3	19.3	19.3	19.2	18.6

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2022	FY2022	FY2023	FY2023	FY2025
Cash and equivalents	176	247	214	235	312	240	288	330	182	158
Receivables										4.29
Inventory	64.8	62.9	81.9	68.9	90.2	98.3	67.1	61.5	69.7	103
Other current assets	5.6	5.33	7.16	4.95	4.97	3.68	7.12	6.1	4.81	4.85
Total current assets	278	340	392	329	425	365	384	418	279	288
Property, plant and equipment	101	103	92	95.2	100	102	97.8	99.8	94.6	94.4
Lease right-of-use assets				31.3		23.8	20	17.7	21.2	23
Goodwill	16.7	17.4	16.8	16.6	17.4	17.7	17.4	17.1	144	138
Intangible assets	34.3	35.2	31.8	29.8	30.8	30.4	32.4	29.9	152	133
Other non-current assets	22.2	20.8	18.1	42.9	62.4	57.9	54.8	54.9	58.8	61.8
Total assets	471	519	554	517	641	578	597	633	748	743
Accounts payable	9.04	11.8	9.95	12.5	18.2	13.5	11	10.1	12	17.3
Accrued liabilities	23.1	22.9	33.7	26.2	32.2	32.4	17.3	9.75	13.6	9.5
Deferred revenue	21.5	3.06	2.65	13.9	16	19.6	20.9	13.9	12.1	10.6
Total current liabilities	138	141	149	136	168	161	144	119	140	129
Lease liabilities				17.3		10.2	7.68	5.14	10.2	12.3
Other non-current liabilities	1.37	1.15	1.26	18.8	19.2	14.3	14.2	12.2	18.2	23.2
Total liabilities	145	156	163	165	199	183	162	136	162	157
Paid-in capital	71.5	76.5	72	59.4	62.5	50	55.6	65.7	75.8	83.5
Retained earnings	265	288	330	306	383	345	392	445	479	466
Other comprehensive income	-11.6	-1.43	-10.4	-13.9	-3.63	0.46	-12.8	-13.7	-22.7	-16.2
Shareholders' equity	325	363	391	352	442	395	434	497	532	533
Total equity	325	363	391	352	442	395	434	497	532	533
Total liabilities and equity	471	519	554	517	641	578	597	633	748	743
Shares outstanding	24.5	24	23.6	21.7	21	19.4	19.2	19.1	19.1	18.3

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2022	FY2022	FY2023	FY2023	FY2025
Net income	100	62.5	126	101	125	117	69.4	63.8	42.1	11.5
Depreciation and amortization	13.5	16.1	16.8	14.7	13.7	13	13.4	12.7	14.5	32.6
Stock-based compensation	16.5	15.5	15	15.5	14.4	14.3	13.3	14.6	14.6	13.8
Deferred income tax	-3.7	19.3	0.61	-3.61	-2.47	-2.83	-6.94	-2.68	-6.74	-7.14
Change in inventory	-1.03	6.05	-23.1	13	-16.8	-14.7	15.8	2.35	-2.12	-34.7
Change in payables	-1.34	3.04	-1.72	1.84	6.08	-4.57	-2.66	-0.43	-1.27	5.2
Cash from operations	137	124	152	127	160	121	104	70.6	61	22.3
Capital expenditures	-32.7	-13.2	-11.4	-16.6	-15.1	-12.8	-10.4	-14.5	-10.1	-13.8
Acquisitions					0	0	-6.53	0	-203	0
Cash from investing	-31.9	-12.9	-69	47.5	-34	-14.2	-12.4	-12	-213	-10.1
Share buybacks	-64.6	-50	-105	-150	-57	-178	-25.4	-11.6	-9.44	-27.5
Cash from financing	-64.9	-50.3	-105	-152	-59.4	-181	-30.1	-14.2	9.55	-40.6
Exchange rate effect	-7.93	11	-11.1	-1.72
Net change in cash	32.2	71.6	-33.3	20.5	78.2	-72.3	47.7	41.9	-149	-23.3
Free cash flow	104	111	141	110	145	108	93.5	56.1	50.9	8.53
Interest paid	0.32	0.02	0.01	0.01	0.71	0.01	0.05	0.07	0.08	0.66
Income taxes paid	52.6	46	70.7	54.9	53	59.5	45.9	42.3	40.4	37.2

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to July 4, 2026; growth uses fiscal years. Valuation uses the share price of $14.50 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	77.4%	Gross profit / revenue.
Operating margin	-0.1%	Operating income / revenue.
EBITDA margin	3.4%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	0.3%	Pre-tax income / revenue.
Net margin	-2.4%	Net income / revenue.
FCF margin	1.7%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	3.0%	Cash from operations / revenue.
Effective tax rate	1,253.0%	Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)	-4.2%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	-3.2%	Net income / average total assets.
Return on invested capital (ROIC)	-0.2%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
SG&A / revenue	36.6%	Selling, general and administrative expense / revenue.
Stock-based pay / revenue	1.6%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	1.3%	Capital expenditures / revenue.
D&A / revenue	3.6%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	8.3%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	-2.5%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	-4.0%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	4.5%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	-3.4%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	-4.8%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income growth, 1y	-43.6%	Operating income vs the same period a year earlier. Only from a positive base.
Operating income CAGR, 3y	-29.7%	Compound annual growth of operating income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating income CAGR, 5y	-26.7%	Compound annual growth of operating income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EBITDA growth, 1y	-13.4%	EBITDA vs the same period a year earlier. Only from a positive base.
EBITDA CAGR, 3y	-16.7%	Compound annual growth of ebitda over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EBITDA CAGR, 5y	-18.1%	Compound annual growth of ebitda over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Net income growth, 1y	-74.4%	Net income vs the same period a year earlier. Only from a positive base.
Net income CAGR, 3y	-46.3%	Compound annual growth of net income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Net income CAGR, 5y	-38.7%	Compound annual growth of net income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EPS growth, 1y	-73.5%	EPS vs the same period a year earlier. Only from a positive base.
EPS CAGR, 3y	-45.5%	Compound annual growth of eps over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EPS CAGR, 5y	-37.0%	Compound annual growth of eps over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y	-63.4%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	-40.1%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow CAGR, 5y	-32.6%	Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Free cash flow growth, 1y	-83.3%	Free cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow CAGR, 3y	-55.0%	Compound annual growth of free cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Free cash flow CAGR, 5y	-43.3%	Compound annual growth of free cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y	0.2%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	7.1%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	3.8%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	-0.7%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	7.6%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	3.0%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	-3.1%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	-1.3%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	-2.7%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	2.66x	Current assets / current liabilities.
Quick ratio	1.63x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	1.60x	(Cash + short-term investments) / current liabilities.
Liabilities / assets	18.8%	Total liabilities / total assets.
Interest coverage	-2.62x	Operating income / interest expense.
Working capital	$175.4M	Current assets - current liabilities.
Goodwill and intangibles / assets	33.2%	(Goodwill + intangible assets) / total assets.
Tangible book value	$292.6M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	1.30x	Revenue / average total assets.
Fixed asset turnover	9.69x	Revenue / average property, plant and equipment.
Inventory turnover	2.39x	Cost of revenue / average inventory.
Days inventory	153 days	365 x average inventory / cost of revenue.
Receivables turnover	274x	Revenue / average receivables.
Days sales outstanding	1 days	365 x average receivables / revenue.
Days payables	27 days	365 x average accounts payable / cost of revenue.
Cash conversion cycle	127 days	Days inventory + days sales outstanding - days payables.
Capex / operating cash flow	42.5%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	-$1.20	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$49.41	Revenue / diluted weighted shares.
FCF per share	$0.86	Free cash flow / diluted weighted shares.
Operating cash flow per share	$1.50	Cash from operations / diluted weighted shares.
Book value per share	$28.51	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$15.85	Tangible book value / shares outstanding.
Cash per share	$9.13	(Cash + short-term investments) / shares outstanding.
Buybacks / FCF	0.0%	Share buybacks / free cash flow, when free cash flow is positive.

Valuation

Metric	Value	How it is calculated
Market cap	$267.9M	Share price x shares outstanding.
Enterprise value	$99.3M	Market cap + total debt - cash - short-term investments.
P/S	0.29x	Market cap / revenue.
P/B	0.51x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	0.92x	Market cap / tangible book value, when positive.
P/FCF	16.8x	Market cap / free cash flow. Only when free cash flow is positive.
P/OCF	9.66x	Market cap / cash from operations, when positive.
EV/Sales	0.11x	Enterprise value / revenue.
EV/EBITDA	3.17x	Enterprise value / EBITDA, when both are positive.
EV/FCF	6.24x	Enterprise value / free cash flow, when both are positive.
FCF yield	5.9%	Free cash flow / market cap.
Earnings yield	-8.3%	Net income / market cap (the inverse of P/E).
Shareholder yield	0.0%	(Dividends paid + share buybacks) / market cap.

What was USANA HEALTH SCIENCES INC's revenue in fiscal 2025?

USANA HEALTH SCIENCES INC reported revenue of $925.3M for fiscal 2025, 8.3% higher than the year before.

Was USANA HEALTH SCIENCES INC profitable in fiscal 2025?

Yes. Net income was $10.8M, a net margin of 1.2%.

How much free cash flow did USANA HEALTH SCIENCES INC generate in fiscal 2025?

Cash from operations of $22.3M minus capital expenditures of $13.8M left free cash flow of $8.5M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to USANA HEALTH SCIENCES INC